A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Rofecoxib [MK0966] in Decreasing the Risk of Prostate Cancer (ViP Study).

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Rofecoxib [MK0966] in Decreasing the Risk of Prostate Cancer (ViP Study).

Completed
Phase of Trial: Phase III

Latest Information Update: 10 May 2017

At a glance

  • Drugs Rofecoxib (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 23 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top